Refine by
Clinical Assay Articles & Analysis
12 news found
In this piece, we talked to the two presenters of the poster “The Validation of a Homologous Recombination Deficiency Assay into Clinical Practice within the NHS”, Elizabeth Ratsma, Pre-Registration Clinical Scientist – Cancer Genomics and Charlotte Flanagan, PhD, Innovation Lead, from The Royal Marsden NHS Foundation Trust. ...
Together, SOPHiA GENETICS and Boundless Bio pioneered the ecDNA Solution (ECS) algorithm to detect the presence of ecDNA using routine clinical next-generation sequencing (NGS) data. ECS is the first ecDNA clinical trial assay and was designed by SOPHiA GENETICS in alignment with FDA guidelines as an Investigational Use Only ...
Ahead of their attendance at this year’s MEDICA event, AgPlus have appointed a new Chief Scientific Officer, Dr Nic Christofides, who has vast experience of finalising late stage clinical assays to ensure commercial success. Of Cypriot descent, Dr Christofides started his career in 1973 at Hammersmith Hospital, London, as a research assistant where he ...
Several new features that may be implicated in clinical pathways, including viral mRNA translation pathway, interferon-gamma signaling, and Innate Immune System, also emerged. ...
ByJADBio
She held several senior business development and management roles at Roche Diagnostics and QIAGEN, around the years that The Netherlands was preparing for primary HPV screening and the industry was developing clinically validated assays to support this new era. It was also then that she collaborated with the scientists who carry decades of dedication to improve ...
Bart Hesselink talks about the clinical validation of QIAGEN’s next generation HPV screening assay on the NeuMoDxTM Molecular Systems. ...
The innovative product enables clinical laboratories and assay developers to meet testing demands and enhance their molecular diagnostics workflows. Clinical diagnostic and hospital laboratories across the United States have ramped up PCR testing over the last year in response to the global COVID-19 pandemic. ...
Currently, no rapid diagnostics exist with clinically actionable performance for early sepsis diagnosis in acute care environments, leaving ED clinicians to balance the benefits of early intervention against the risks of unnecessary and resource-intensive interventions. ...
Lastly, and importantly, Matrix Plus enabled high throughput cardiotoxicity screening using mature human cardiomyocytes with validation utilizing reference compounds recommended for the evolving Comprehensive In Vitro Proarrhythmia Assay (CiPA) coordinated by the Health and Environmental Sciences Institute (HESI). ...
The Oncomine Myeloid Assay GX* is the first in a series of clinical research assays available from the new suite of hematology-oncology solutions. ...
Thermo Fisher Scientific, the world leader in serving science, announced today that it has expanded its European offering of pre-validated assays for the Thermo Scientific Cascadion SM Clinical Analyzer with the addition of the CE/IVD marked Cascadion SM Immunosuppressants (ISD) Panel. ...
FUSION GENOMICS Corporation is a molecular diagnostic company that develops clinical assays using next-generation sequencing technologies to characterize infectious disease agents of clinical and global importance. ...